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Abstract
Background: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of
progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present
outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibrotic drugs tested in the Novel
Therapies in Resistant FSGS (FONT) study.
Methods: 21 patients – 12 males and 9 females, age 16.0 ± 7.5 yr, and estimated GFR (GFRe) 121 ± 56 mL/min/
1.73 m2 – received adalimumab (n = 10), 24 mg/m2 every 14 days or rosiglitazone (n = 11), 3 mg/m2 per day for
16 weeks. The change in GFRe per month prior to entry and after completion of the Phase I trial was compared.
Results: 19 patients completed the 16-week FONT treatment phase. The observation period pre-FONT was 18.3 ±
10.2 months and 16.1 ± 5.7 months after the study. A similar percentage of patients, 71% and 56%, in the
rosiglitazone and adalimumab cohorts, respectively, had stabilization in GFRe, defined as a reduced negative slope
of the line plotting GFRe versus time without requiring renal replacement therapy after completion of the FONT
treatment period (P = 0.63).
Conclusion: Nearly 50% of patients with resistant FSGS who receive novel antifibrotic agents may have a legacy
effect with delayed deterioration in kidney function after completion of therapy. Based on this proof-of-concept
preliminary study, we recommend long-term follow-up of patients enrolled in clinical trials to ascertain a more
comprehensive assessment of the efficacy of experimental treatments.
Background
Primary focal segmental glomerulosclerosis (FSGS) is
increasing in frequency throughout the world [1]. It
usually presents with isolated proteinuria or overt
nephrotic syndrome in both pediatric and adult patients
[2-4]. The cause of this glomerulopathy remains
unknown and there are no proven treatments that con-
sistently induce complete remission of proteinuria [5].
Patients who are resistant to corticosteroids and other
immunosuppressive medications are at substantial risk
of progression to chronic kidney disease (CKD) stage V
[6-8]. There is an urgent need to develop new strategies
to delay or prevent loss of renal function in this patient
cohort.
The primary purpose of the first portion of the Novel
Therapies for Resistant FSGS (FONT) study is to evalu-
ate the safety, tolerability, and pharmacokinetic charac-
teristics of novel pharmacological agents that may be
antifibrotic and renoprotective. The first two agents
selected for testing were rosiglitazone, a peroxisome-
proliferator activated receptor-g, and adalimumab, a
human monoclonal antibody to tumor necrosis factor-a.
Rosiglitazone is prescribed to children and adults with
type 1 and type 2 diabetes [9], while adalimumab is uti-
lized in patients with rheumatoid arthritis and inflam-
matory bowel disease [10]. The main side effects of
rosiglitazone are edema, anemia, congestive heart failure
and fractures; the most serious adverse events related to
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adalimumab use are infections and malignancy [9,10]. In
this report, we summarize the kidney function outcomes
at follow-up after completion of the Phase I study to
obtain preliminary data about the legacy effect of these
two drugs, namely their capacity to alter the natural his-
tory of the disease in children and young adults with
refractory primary FSGS.
Methods
Patients
Patients, 2-41 years of age, with biopsy-confirmed pri-
mary FSGS and calculated GFR > 40 mL/min/1.73 m2,
were eligible to participate in the FONT study. They
were resistant to a standard course of glucocorticoids
and had either been treated unsuccessfully with myco-
phenolate mofetil, azathioprine, cyclosporine, or tacroli-
mus in the past. The protocol was approved by the
Institutional Review Board at each site and patient (and/
or parent/guardian) consent was obtained prior to
enrollment.
Participants were off all immunosuppressive medica-
tions for at least 4 weeks before enrollment. Therapy
with angiotensin converting enzyme inhibitors and/or
angiotensin receptor blocker drugs was permitted, pro-
vided dosages were maintained for the duration of the
study. Patients were assigned to receive either rosiglita-
zone or adalimumab. The total rosiglitazone dose was 3
mg/m2 per day given orally twice a day, with a maxi-
mum daily dosage of 8 mg. The adalimumab dose was
24 mg/m2 given as a subcutaneous injection every 14
days, with a maximum single dose of 40 mg. Both
experimental agents were given for 16 weeks and
patients were evaluated at week 1, 2, 4, 8, 12, and 16.
The following clinical and laboratory data were mea-
sured at each assessment: blood pressure, height, weight,
edema, serum creatinine, estimated GFR (Cockroft-
Gault equation if ≥ 18 years and Schwartz formula for <
18 years), urinary protein:creatinine ratio (Up:cr) in a
first morning specimen, serum albumin, and blood glu-
cose. In adolescents who passed their 18th birthday dur-
ing the study, the Schwartz formula was used
throughout the observation period. A kidney biopsy at
the start or completion of the FONT Treatment Period
or at the last follow-up visit was not part of the study
protocol. Nineteen out of the 21 patients enrolled in the
trial completed the 4-month Treatment Period and
laboratory evaluation.
The attending physician of each patient was contacted
and asked to provide the patient’s serum creatinine con-
centration and GFRe value for up to 25 months prior to
enrollment in the FONT trial. In addition, data about
the clinical status and laboratory values at the most
recent follow-up assessment were obtained. The treat-
ment after completion of the FONT study was left to
the discretion of site nephrologist. In particular, infor-
mation about current renal status, new medical pro-
blems, blood pressure, urinary protein excretion, and
GFRe were tabulated. Laboratory tests were performed
in local facilities and were not standardized in a central
laboratory.
The slope of the line displaying the GFRe over time
was calculated for the period prior to enrollment in the
FONT Phase I study and for the follow-up period after
completion of the 16-week experimental Treatment
Period.
Statistical methods
Data are presented as mean ± SD. Descriptive analyses
for demographic variables and laboratories include
mean, standard deviation, and median as appropriate.
Differences between groups were assessed with a t-test.
Results were considered statistically significant if the P
value was less than 0.05.
Results
The clinical status of the 21 patients who participated in
the FONT Phase I study at the time of enrollment is
summarized in Table 1. The very high GFRe values
were obtained in the young children who had corre-
spondingly low serum creatinine concentrations. There
were no significant differences between the patients who
were assigned to receive adalimumab or rosiglitazone.
The short-term results of the 16-week experimental
drug Treatment Period have been described previously
[11,12]. Briefly, both agents were generally safe and well
tolerated by the patients with resistant FSGS. Two
patients were withdrawn from the study before complet-
ing the full 16-week Treatment Period - one child
assigned to rosiglitazone developed a possible drug
allergy (hives and penile swelling), necessitating disconti-
nuation of the drug after 6 weeks and one adult treated
with adalimumab was removed from the study after 12
weeks because of refractory edema that required alternate
therapy for control. No patient developed significant
change in GFRe or was started on renal replacement
therapy during the 16-week FONT Treatment Period.
Table 1 FONT I: Clinical and laboratory features
Result
Age (yr) 16.0 ± 7.5
Pubertal status (<Tanner 3:≥ Tanner 3) 9:12
Gender (M:F) 12:9
Ethnicity (White:Black:Hispanic:Other) 11:5:2:3
Ht (cm) 151 ± 24
Wt (kg) 54 ± 25
Up:cr (mg:mg) 9.3 ± 8.8
GFRe (ml/min/1.73 m2) 121 ± 56
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The duration of the follow-up period was similar in
the two groups, 18 ± 6 (range: 7-26) and 14 ± 5 (range:
6-20) months in the rosiglitazone and adalimumab
groups, respectively (P = 0.12). All of the patients were
receiving an angiotensin converting enzyme inhibitor
and/or an angiotensin receptor blocker and 10 out of 21
were treated with a statin.
During the observation period after completion of the
FONT study, 5 patients progressed to CKD stage V - 4
enrolled to the rosiglitazone arm and 1 in the adalimu-
mab group (P = 0.31). Figures 1 and 2 illustrate the lin-
ear plots of GFRe versus months of observation prior to
enrollment in the FONT Phase I trial and after comple-
tion of the 16-week experimental Treatment Period for
each patient assigned to rosiglitazone (Figure 1) or to
adalimumab (Figure 2). The change in the slope of the
line relating GFRe versus time during the period before
and after the FONT study period is summarized in
Table 2. There was no significant difference in the
change in this value between the group of patients trea-
ted with adalimumab compared to those who received
rosiglitazone (P = 0.74). The impact of the two FONT
therapies on the rate of change in kidney function was
not significantly altered if the results of the 5 patients
who progressed to CKD Stage V were excluded from
the analysis, 1.72 ± 4.10 and 0.49 ± 6.02 ml/min/1.73
m2/month in the rosiglitazone and adalimumab groups,
respectively (P = 0.65). Overall, among those patients
who did not progress to CKD Stage V requiring initia-
tion of renal replacement therapy, a similar percentage
in each cohort 5/9(56%) versus 5/7 (71%) displayed sta-
bilization in GFRe therapy during the observation period
after completion of the FONT study, based on a less
steep slope of the GFRe versus time line (P = 0.68).
Discussion
There is an urgent need to systematically develop and
evaluate novel therapies for patients with resistant pri-
mary FSGS because the disease is becoming more preva-
lent and the risk of progressive loss of kidney function is
especially high in those who do not achieve a reduction
in proteinuria in response to standard immunosuppres-
sive therapy. The rationale for the FONT trial is that
absent a consistent immunolopathological target of
treatment, interventions designed to reduce renal fibro-
sis offer the best hope of stabilizing kidney function and
preventing or attenuating the steady decline in kidney
function and the need for renal replacement therapy.
This approach is feasible in patients with primary FSGS,
irrespective of whether it is linked to genetic mutations
in podocyte proteins or if there is no demonstrable
molecular basis for the glomerular disease [13].
The results of FONT Phase I study indicate that adali-
mumab and rosiglitazone are safe and generally well tol-
erated in patients with primary FSGS. In addition,
pharmacokinetic analyses indicate that because of a
reduced area under the curve and enhanced clearance,
the dosage of both agents needs to be modified upward
in order to achieve drug levels that are comparable to
those observed when the drugs are used for FDA
approved indications in patients with normal kidney
function and without nephrotic-range proteinuria
[11,12]. The outcomes of the two Phase I trials justify
moving forward with the assessment of these two
Figure 1 This graph illustrates the estimated GFR versus time (in months) prior to and after completion of the 6-month FONT
Treatment Period in patients assigned to rosiglitazone.
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agents. Clarification of any benefit of rosiglitazone and/
or adalimumab therapy requires the performance of a
randomized clinical trial in which the efficacy of these
antifibrotic agents is compared to a parallel group given
conservative medical therapy alone - an angiotensin
converting enzyme inhibitor, an angiotensin receptor
blocker, and a statin. This question hopefully will be
answered in the ongoing FONT Phase II trial.
Determination of the efficacy of adalimumab and rosi-
glitazone as antifibrotic agents in resistant primary
FSGS will require performance of Phase II and III ran-
domized controlled studies that enroll a sufficient num-
ber of patients and have statistical power to
demonstrate a clinically significant effect on hard
endpoints such as change in GFRe or on surrogate mar-
kers like proteinuria. However, therapeutic treatment
period and follow-up interval in clinical trials are often
not long enough to adequately demonstrate differences
in clinically relevant hard renal outcomes such as dou-
bling of serum creatinine and need to initiate renal
replacement therapy [14]. Therefore, an important con-
sideration in evaluating novel therapies for renal disease
is to ascertain whether the impact of the experimental
intervention is prolonged and is manifest even after dis-
continuation of the study drug. This accounts for our
focus in this report on GFRe rather than surrogate mar-
kers like proteinuria and blood pressure that are detailed
in the primary reports of the FONT Phase I trials
Figure 2 This graph illustrates the estimated GFR versus time (in months) prior to and after completion of the 6-month FONT
Treatment Period in patients assigned to adalimumab.
Table 2 Change in GFRe in response to FONT study intervention: Rosiglitazone versus adalimumab
Patient # Rosiglitazone Adalimumab
Follow-up interval (months) ΔGFRe slope* Follow-up interval (months) ΔGFRe slope*
Pre Post Pre Post
1 12 21 7.91 6 10 -0.39
2 25 19 0.46 16 6 4.04
3 7 26 -5.73 14 18 -2.28
4 23 20 0.91 11 20 0.12
5 12 20 -4.01 50 17 6.35
6 12 9 1.96 6 17 10.36
7 14 17 6.42 23 16 0
8 12 13 4.23 18 16 1.33
9 24 25 3.58 32 7 0.62
10 25 20 -1.65 23 14 -11.69
11 20 7 3.23
Mean ± SD 16.8 ± 6.4 18.0 ± 6.0 1.72 ± 4.10 20 ± 13 14 ± 5 0.84 ± 5.78
*The change in slope is reported as ml/min/1.73 m2/month
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[11,12]. The FDA has strongly recommended that this
type of assessment be incorporated into the analysis of
efficacy novel therapies for glomerular disorders [15].
The ‘legacy” effect has been examined in studies that
tested interventions to lower serum glucose concentra-
tion and blood pressure in patients with diabetes
[16-18]. However, this type of analysis has not become a
standard element in the design of clinical trials in
nephrology, especially those involving pediatric patients.
This report represents an initial step in this direction
by comparing the slope of the GFRe versus time curve
prior to and after treatment with adalimumab or rosigli-
tazone in the FONT Phase I study. To the best of our
knowledge, this is first time such an assessment has
been conducted in patients with primary FSGS. The
results indicate that approximately 30% of 21 patients
had a clinically measurable slowing of the rate of dete-
rioration in kidney function for up to a year after the
16-week treatment with either adalimumab or rosiglita-
zone. We acknowledge that the number of patients in
each group is small, consistent with a Phase I study.
Therefore, it is premature to draw any conclusion about
the efficacy of the test therapies without studies invol-
ving a larger cohort given the antifibrotic agents for an
extended period or to make any meaningful comparison
between the two treatments.
There are several limitations to this study. The use of
formulas to estimate GFR in children and adults is the
subject of ongoing controversy. Newer formulas have
been proposed that may predict the level of kidney func-
tion more accurately [19,20]. The age-appropriate
Schwartz and Cockcroft-Gault formulas were used con-
sistently for the entire study period and, therefore,
changes in GFRe should not be effected by shortcom-
ings in the formulas, per se. We did not rely on the
MDRD formula which is inaccurate in patients with
GFRe greater than 60 ml/min/1.73 m2 [21]. In addition,
the serum creatinine measurements used to calculate
GFRe during follow-up were not performed in a central
laboratory or standardized. Nonetheless, they were con-
sistent for each patient and should reflect disease pro-
gression in individual cases.
We acknowledge that it would be premature to specu-
late on the frequency and magnitude of long-term bene-
fit of antifibrotic therapy based on this small relatively
heterogeneous cohort. The clinical ramifications of the
change in the slope of the GFRe versus time line needs
clarification in larger series of patients. However, one
cannot gainsay the value of studies like the FONT trial
in which there are well defined criteria for enrollment
and patient management is controlled. Finally, because
the follow-up was conducted after completion of the
formal protocol, the treatments that the patients in each
group received were uncontrolled. Therefore, we cannot
attribute any beneficial long-term effect on GFRe to a
delayed effect of the FONT antifibrotic interventions or
to the uncontrolled therapies prescribed during the
post-FONT treatment period.
Conclusion
The information in this preliminary report supplements
our projected effect of these drugs in a Phase II trial, in
which we have calculated the sample size based on the
occurrence of a 50% reduction in proteinuria in 30% of
patients are treated with adalimumab or rosiglitazone
versus 10% of patients who are given conservative medi-
cal therapy (angiotensin converting enzyme inhibitor,
angiotensin receptor blocker, and HMG-CoA reductase
inhibitor). The findings of long-term follow-up from the
FONT Phase I studies need to be extended and con-
firmed in larger Phase II and III trials. However, they
suggest that the use of antifibrotic agents for a defined
period of time may have a legacy effect and represent a
viable strategy to preserve kidney function in glomerular
disorders like FSGS that are resistant to corticosteroids
and other immunosuppressive drugs. Based on this pre-
liminary proof-of-concept study, we recommend that
long-term follow-up be incorporated into the study
design of all clinical trials in nephrology that include
pediatric and/or adult patients in order to enable more
comprehensive assessment of the effect of the experi-
mental treatments under evaluation (word count: 2301).
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